BrainStorm Cell Therapeutics Inc. has announced new survival data from its Expanded Access Program (EAP) for NurOwn®, a treatment for amyotrophic lateral sclerosis (ALS). The program observed that 90% of the 10 participants, who had previously completed a Phase 3 clinical trial, survived over five years from the onset of ALS symptoms. This contrasts with the typical survival rate, where approximately 10% of individuals with ALS survive beyond five years. The median survival in the EAP cohort was 6.8 years. This data was collected through publicly available records and highlights the potential of NurOwn in extending survival in ALS patients. The findings will support the upcoming Phase 3b trial of NurOwn, which will be conducted under an FDA Special Protocol Assessment $(SPA.UK)$.